Literature DB >> 35851661

Association between thyroid function and comorbid anxiety in first-episode and drug naïve patients with major depressive disorder.

Wanqiu Yang1,2, Miao Qu3, Rui Jiang4, XiaoE Lang5, Xiang-Yang Zhang6,7.   

Abstract

OBJECTIVE: Existing studies have shown that thyroid dysfunction is associated with depression. However, its role in major depressive disorder (MDD) with comorbid anxiety remains unclear. The main purpose of this study was to compare thyroid function in a large sample of first episode drug naïve (FEDN) MDD patients with and without anxiety.
METHODS: This cross-sectional study examined 1718 outpatients who were drug-naïve and diagnosed as MDD at first episode. Socio-demographic and clinical data, as well as thyroid function-related parameters, including free thyroxine (FT4), free triiodothyronine (FT3), thyroid-stimulating hormone (TSH), thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin (TGAb), were evaluated. The Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA) and the positive subscale of the Positive and Negative Syndrome Scale (PANSS) were used to evaluate depressive, anxiety and psychotic symptoms, respectively.
RESULTS: Compared to MDD patients without anxiety, MDD patients with anxiety were more likely to have more suicide attempts and psychotic symptoms, as well as higher serum levels of TSH, TPOAb and TGAb (all p < 0.001). Among patients with abnormally elevated serum TSH, TPOAb, and TGAb, 83.5% (872/1044), 89.3% (391/438) and 89.6% (266/297) had comorbid anxiety disorders, respectively. The odds ratio between patients with comorbid and without comorbid anxiety was 1.657 (95% CI 1.304-2.105) for elevated TSH levels, 1.943 (95% CI 1.444-2.613) for elevated TGAb levels, and 2.448 (95% CI 1.760-3.403) for elevated TPOAb levels. Furthermore, multivariable linear analysis showed that elevated TSH and TGAb were significant predictors of anxiety in MDD patients.
CONCLUSIONS: Our results suggest that comorbid anxiety in FEDN MDD patients is positively associated with elevated TSH and TGAb levels, which may be promising biomarkers of comorbid anxiety in MDD patients. Clinical treatment of impaired thyroid function may be useful for comorbid anxiety in MDD patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Anxiety; Depression; TGAb; TPOAb; TSH; Thyroid

Year:  2022        PMID: 35851661     DOI: 10.1007/s00406-022-01457-x

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.760


  33 in total

1.  Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project.

Authors:  Katja Wiethoff; Michael Bauer; Thomas C Baghai; Hans-Jürgen Möller; Robert Fisher; Dorothea Hollinde; Julia Kiermeir; Iris Hauth; Gerd Laux; Joachim Cordes; Peter Brieger; Klaus-Thomas Kronmüller; Joachim Zeiler; Mazda Adli
Journal:  J Clin Psychiatry       Date:  2010-07-13       Impact factor: 4.384

2.  Depression, subthreshold depression and comorbid anxiety symptoms in older Europeans: results from the EURODEP concerted action.

Authors:  Arjan W Braam; John R M Copeland; Philippe A E G Delespaul; Aartjan T F Beekman; Ariel Como; Michael Dewey; Manfred Fichter; Tjalling J Holwerda; Brian A Lawlor; Antonio Lobo; Hallgrímur Magnússon; Martin J Prince; Friedel Reischies; Kenneth C Wilson; Ingmar Skoog
Journal:  J Affect Disord       Date:  2013-11-25       Impact factor: 4.839

Review 3.  Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa.

Authors:  Robert Dantzer
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

4.  Psychosocial features associated with lifetime comorbidity of major depression and anxiety disorders among a community sample of mid-life women: the SWAN mental health study.

Authors:  Jill M Cyranowski; Laura L Schott; Howard M Kravitz; Charlotte Brown; Rebecca C Thurston; Hadine Joffe; Karen A Matthews; Joyce T Bromberger
Journal:  Depress Anxiety       Date:  2012-08-28       Impact factor: 6.505

5.  Treatment inadequacy in primary and specialized care patients with depressive and/or anxiety disorders.

Authors:  Pierre M Bet; Jacqueline G Hugtenburg; Brenda W J H Penninx; Anton van Balkom; Willem A Nolen; Witte J G Hoogendijk
Journal:  Psychiatry Res       Date:  2013-07-11       Impact factor: 3.222

6.  Suicide in late-life depression with and without comorbid anxiety disorders.

Authors:  Richard C Oude Voshaar; Date C van der Veen; Isabelle Hunt; Nav Kapur
Journal:  Int J Geriatr Psychiatry       Date:  2015-06-11       Impact factor: 3.485

7.  Thyroid and adrenal axis in major depression: a controlled study in outpatients.

Authors:  Jantien P Brouwer; Bente C Appelhof; Witte J G Hoogendijk; Jochanan Huyser; Erik Endert; Cassandra Zuketto; Aart H Schene; Jan G P Tijssen; Richard Van Dyck; Wilmar M Wiersinga; Eric Fliers
Journal:  Eur J Endocrinol       Date:  2005-02       Impact factor: 6.664

Review 8.  Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century.

Authors:  Ronald C Kessler; Kathleen R Merikangas; Philip S Wang
Journal:  Annu Rev Clin Psychol       Date:  2007       Impact factor: 18.561

Review 9.  Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications.

Authors:  Zezhi Li; Meihua Ruan; Jun Chen; Yiru Fang
Journal:  Neurosci Bull       Date:  2021-02-13       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.